WALTHAM, Mass., March 10, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Viridian Therapeutics Inc (Symbol: VRDN) entered into oversold territory, hitting an RSI ...
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback